**Pneumococcal Polysaccharide (PPSV23) Vaccine Recommendations:**

- Persons 2-64 years of age who have a chronic health problem (See Table 1)
- *Persons 2-64 years of age who are immunocompromised, have cerebrospinal fluid (CSF) leaks or cochlear implants (See Table 1)
- Adults 19-64 years of age who: Have asthma, smoke cigarettes (should receive smoking cessation counseling) or experiencing alcoholism
- All adults \(\geq 65\) years of age should routinely receive a single dose of PPSV23

**PPSV23 Recommendations for High-Risk Children Previously Immunized with pneumococcal conjugate vaccine (PCV13):**

- DO NOT administer PCV13 and PPSV23 at the same time
- Children who have previously received PCV13 and are among risk groups for which PPSV23 is recommended should receive 1 dose of PPSV23 at age 2 years (at least 8 weeks after the last dose of PCV13), as they will benefit from additional pneumococcal serotype immunity stimulated by PPSV23 (See Table 2)
- Immunocompromised children should receive a 2nd dose of PPSV23 five years after the 1st dose of PPSV23
- Complete PCV13 and/or PPSV23 vaccination at least 2 weeks prior to surgery or initiation of therapy when elective splenectomy, immunocompromising therapy, or cochlear implant placement is planned

**Advisory Committee on Immunization Practices (ACIP) Recommendations for PCV13 and PPSV23 Use in Immunocompromised Children Aged 6-18 years:** For more information see [http://publichealth.lacounty.gov/ip/providers/B71/B71_PCV.pdf](http://publichealth.lacounty.gov/ip/providers/B71/B71_PCV.pdf)

- **PPSV23-naïve children**: ACIP recommends that children aged 6-18 years who are immunocompromised, have CSF leaks or cochlear implants who have not received PCV13 receive a single PCV13 dose first, followed by a dose of PPSV23 eight weeks later
- **Previous vaccination with PPSV23**: Children 6 through 18 years who are immunocompromised, have CSF leaks or cochlear implants who have not received PCV13, and who previously received 1 dose of PPSV23 should receive a single PCV13 dose 8 weeks after the last PPSV23 dose, even if they have received PCV7. If indicated give a 2nd PPSV23 dose 5 years after the first PPSV23 dose. These children should not receive more than 2 doses of PPSV23 before age 65 years.

**Contraindications**
- A serious allergic reaction to a vaccine component or following a prior dose
- Pregnancy

**Precautions**
- A moderate or severe acute illness until condition improves or resolves

**Adverse Reactions**
- **Local**: redness or pain at administration site
- **Systemic**: fever, muscle aches, or more severe local reactions

**Storage & Handling**
- Store vaccine between 35° and 46°F (aim for 40°F)
- DO NOT freeze vaccine

---

**Vaccine Dosage & Administration**

<table>
<thead>
<tr>
<th>Vaccine</th>
<th>Dosage &amp; Administration</th>
<th>Primary Schedule</th>
<th>Recommended Age</th>
<th>Indication for Use</th>
</tr>
</thead>
<tbody>
<tr>
<td>PPSV23 (Pneumovax®23) Merck</td>
<td>0.5 mL IM</td>
<td>Single dose with revaccination of some individuals*</td>
<td>2 years and older</td>
<td>Vaccination against invasive pneumococcal disease types included in the vaccine</td>
</tr>
</tbody>
</table>

---

**For more information on 23-Valent Pneumococcal Polysaccharide vaccine or any other recommended vaccine, visit the Los Angeles County Vaccine Preventable Disease Control Program website at [http://publichealth.lacounty.gov/ip/providers/B71/VPPSV.pdf](http://publichealth.lacounty.gov/ip/providers/B71/VPPSV.pdf) or call (213) 351-7800.**
**Table 1.**

<table>
<thead>
<tr>
<th>Chronic Conditions</th>
<th>Immunocompromising/High Risk Conditions</th>
</tr>
</thead>
<tbody>
<tr>
<td>Heart, lung or liver disease, diabetes,</td>
<td>Anatomic or functional asplenia; CSF leaks; chronic renal failure; cochlear implant; congenital or acquired immunodeficiency; HIV infection; Hodgkin disease; leukemias, lymphomas &amp; other diseases; malignant neoplasms; multiple myeloma; nephrotic syndrome; Sickle cell disease &amp; other hemoglobinopathies; solid organ transplantation</td>
</tr>
</tbody>
</table>

**Table 2.**

<table>
<thead>
<tr>
<th>AGE</th>
<th>NUMBER OF PCV13 DOSES RECEIVED</th>
<th>NUMBER OF RECOMMENDED PPSV23 DOSES</th>
</tr>
</thead>
<tbody>
<tr>
<td>24-71 months with an underlying medical condition</td>
<td>2 doses received – 3rd dose 8 weeks after the most recent dose and 4th dose 8 weeks later</td>
<td>1 dose at least 8 weeks after the last dose of PCV13</td>
</tr>
<tr>
<td></td>
<td>1 dose received – 2&lt;sup&gt;nd&lt;/sup&gt; dose 8 weeks after the most recent dose</td>
<td>1 dose of PPSV23 at least 8 weeks later</td>
</tr>
</tbody>
</table>

**Use of PPSV23 and PCV13 in high-risk adults < 65 years:**
- DO NOT administer PCV13 and PPSV23 at the same time, the minimum interval between PCV13 and PPSV23 is 8 weeks
- Adults ≤ 64 years of age who are immunocompromised (See Table 1)
- Administer pneumococcal conjugate vaccine (PCV13) first. Instruct patient to return in 8 weeks for PPSV23
- If PPSV23 is given first, wait 1 year before giving PCV13
- The patient should receive a 2<sup>nd</sup> dose of PPSV23 five years after the 1<sup>st</sup> dose of PPSV23

**Recommendations for routine use of PPSV23 and PCV13 in adults ≥65 years:**
- DO NOT administer PCV13 and PPSV23 at the same time
- All Adults aged ≥65 years who received PPSV23 before age 65 years for any indication: Administer a 2<sup>nd</sup> dose of PPSV23 five years after the 1<sup>st</sup> dose. Do NOT administer additional doses of PPSV23 following the dose administered at age ≥65 years.
- In June 2019, the ACIP no longer routinely recommends PCV13 for all immunocompetent adults aged ≥65 years, who do NOT have CSF leak, or cochlear implant and who have not previously received PCV13. The ACIP recommends PPSV13 based on shared clinical decision-making**.
- Shared Clinical Decision-Making for PCV13 for all immunocompetent adults aged ≥65 years, who do NOT have CSF leak, or cochlear implant: If the patient resides in a nursing home, other long-term care facility, in a setting with low pediatric PCV13 uptake, or traveling to settings with no pediatric PCV13 program administer PCV13 one year prior to PPSV23
- Adults aged ≥65 years who are immunocompromised, have CSF leaks or cochlear implants and have NOT previously received pneumococcal vaccine or whose previous vaccination history is unknown: Administer PCV13. Instruct patient to return in 8 weeks for PPSV23.
- Adults aged ≥65 years who are immunocompromised, have CSF leaks or cochlear implants and have previously received pneumococcal vaccine PPSV23: Administer one PCV13 dose ≥1 year after the last PPSV23 dose. If PCV13 was given before age 65 years, no additional PCV13 is needed.

**Reference:**